|
Mar 29
|
Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
|
|
Mar 29
|
Humacyte price target lowered to $8 from $10 at BTIG
|
|
Mar 3
|
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
|
|
Feb 27
|
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
|
|
Feb 27
|
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
|
|
Feb 26
|
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
|
|
Sep 26
|
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
|
|
Aug 27
|
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
|
|
Jul 16
|
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
|
|
Jun 25
|
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
|
|
Jun 17
|
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
|
|
May 13
|
Humacyte to Participate at Upcoming Investor Conferences in May
|
|
May 10
|
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances
|
|
May 10
|
Humacyte First Quarter 2024 Financial Results and Business Update
|
|
May 6
|
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
|
|
Mar 26
|
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
|
|
Mar 23
|
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
|
|
Mar 18
|
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
|
|
Feb 9
|
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
|